Document Detail


The intraocular pressure-lowering effect of prostaglandin analogs combined with topical β-blocker therapy: a systematic review and meta-analysis.
MedLine Citation:
PMID:  20619459     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To estimate the intraocular pressure (IOP)-lowering effect of prostaglandin analogs (PGAs) when added to topical β-blocker (BB) therapy. DESIGN: Systematic review and meta-analyses of randomized clinical trials. PARTICIPANTS: Twenty-nine articles reporting on 33 study arms and 3 control arms. METHODS: Articles published between January 1, 1990, and August 18, 2009, were identified in relevant databases. The pooled IOP-lowering effects at the 1- to 3-month follow-ups were calculated by performing random effects meta-analyses. MAIN OUTCOME MEASURES: Absolute and relative change in IOP for mean diurnal curve and highest and lowest IOP decrease on the diurnal IOP curve. RESULTS: Adding 0.005% latanoprost in the evening to 0.5% timolol twice daily resulted in a pooled change of -6.3 mmHg (95% CI, -7.1 to -5.5 mmHg, mean IOP curve); switching to the fixed combination of 0.5% timolol and 0.005% latanoprost in the morning resulted in a pooled change of -2.8 mmHg (95% CI, -3.3 to -2.3 mmHg, mean IOP curve). Starting with any fixed combination of 0.5% timolol and a PGA in the morning resulted in a pooled change of -8.4 mmHg (95% CI, -9.1 to -7.6 mmHg, mean IOP curve) and varied between -9.1 mmHg (95% CI, -9.9 to -8.2 mmHg, highest) and -7.9 mmHg (95% CI, -8.5 to -7.2 mmHg, lowest); starting with any fixed combination of 0.5% timolol and a PGA in the evening resulted in a pooled change of -8.6 (95% CI, -9.2 to -8.0 mmHg, mean IOP curve) and varied between -10.1 mmHg (95% CI, -11.0 to -9.2 mmHg, highest) and -7.3 mmHg (95% CI, -8.1 to -6.4 mmHg, lowest). CONCLUSIONS: The concomitant use of latanoprost and timolol leads to a larger additional IOP reduction when compared with the fixed combination. There is no difference in mean IOP-lowering effect between evening and morning dosing of a fixed combination of timolol and a PGA, although the largest IOP decreases are seen with evening dosing. These findings are explained by differences in study design. When time points of IOP measurements close to the peak or trough moment of a drug are included, the IOP-lowering effect will be overestimated or underestimated, respectively. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
Authors:
Carroll A B Webers; Henny J M Beckers; Maurice P Zeegers; Rudy M M A Nuijts; Fred Hendrikse; Jan S A G Schouten
Related Documents :
18801579 - The accuracy of continued clinical use of goldmann applanation tonometers with known ca...
12836809 - Comparison of brimonidine/latanoprost and timolol/dorzolamide: two randomized, double-m...
1428569 - The effects of dopamine, haloperidol and bromocriptine on intraocular pressure.
11558809 - A randomized trial of the long-term effects of digital ocular compression in the late p...
3595569 - Effect of pretreatment with propranolol on intra-ocular pressure changes during inducti...
2663749 - The effect of betablockers with and without isa on tonographic outflow facility.
17281219 - Elucidating nonlinear baroreflex and respiratory contributions to heart rate variabilit...
17606839 - The spironolactone, amiloride, losartan, and thiazide (salt) double-blind crossover tri...
19890369 - Despite evidence-based guidelines, systolic blood pressure remains inadequately control...
Publication Detail:
Type:  Journal Article; Meta-Analysis; Review    
Journal Detail:
Title:  Ophthalmology     Volume:  117     ISSN:  1549-4713     ISO Abbreviation:  Ophthalmology     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-25     Completed Date:  2010-11-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7802443     Medline TA:  Ophthalmology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2067-74.e1-6     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Affiliation:
Department of Ophthalmology, Maastricht University Hospital, Maastricht, The Netherlands. c.webers@mumc.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Topical
Adrenergic beta-Antagonists / administration & dosage,  therapeutic use*
Antihypertensive Agents / administration & dosage,  therapeutic use*
Drug Therapy, Combination
Glaucoma, Open-Angle / drug therapy*
Humans
Intraocular Pressure / drug effects*
Prostaglandins F, Synthetic / administration & dosage,  therapeutic use*
Randomized Controlled Trials as Topic
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Antihypertensive Agents; 0/Prostaglandins F, Synthetic

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Molecular mechanism underlying the inflammatory complication of leptin in macrophages.
Next Document:  The utility of the monocular trial: data from the ocular hypertension treatment study.